A retrospective analysis of the women hospitalized and treated due to anemia caused by gynecological pathologies: the role of intravenous iron (ferric carboxymaltose) and blood transfusion in clinical practice

Minerva Obstet Gynecol. 2023 Oct;75(5):399-404. doi: 10.23736/S2724-606X.22.05044-8. Epub 2022 Apr 7.

Abstract

Background: Gynecological pathologies are an important cause of anemia in women. In this study, we aimed to evaluate women who had been hospitalized because of anemia (Hb level <10 g/dL) caused by gynecologic pathologies and treated with either intravenous iron (ferric carboxymaltose) or blood transfusion.

Methods: This retrospective cross-sectional study was performed in a tertiary care center. Women who were hospitalized with the diagnosis of anemia with Hb level<10 g/dL and abnormal uterine bleeding between March 2015- September 2017 in the gynecology clinic were enrolled in the study. Hemoglobin levels, hemoglobin changes, uterine pathology and treatment of patients were recorded and compared.

Results: One hundred and fifteen women received red blood cell transfusion and 100 women were treated with intravenous ferric carboxymaltose. The mean age of the women was 45.1±6.1 (22-57) years. Although the mean Hb levels were higher in the iv-iron replacement group at the end of the one month (P=0.001), the mean increase in Hb levels was similar between two treatment modalities (P=0.101). Among the anemic women who required surgery, iv iron replacement was the first choice in 75.9% of women; 34.1% received red blood cell transfusion in the preoperative period.

Conclusions: Gynecological pathologies are a common cause of anemia in reproductive age women and intravenous carboxymaltose treatment is a safe and cheaper alternative of blood-transfusion in appropriate cases to elevate the Hb levels in the preoperative period.

MeSH terms

  • Adult
  • Anemia* / drug therapy
  • Anemia* / etiology
  • Blood Transfusion*
  • Cross-Sectional Studies
  • Female
  • Ferric Compounds / administration & dosage
  • Hematinics* / adverse effects
  • Hemoglobins / therapeutic use
  • Humans
  • Iron* / administration & dosage
  • Iron* / therapeutic use
  • Middle Aged
  • Retrospective Studies

Substances

  • ferric carboxymaltose
  • ferryl iron
  • Hematinics
  • Hemoglobins
  • Iron
  • Ferric Compounds